ResultsIQ

ResultsIQ › Latest results › Nephrocare Health Services Limited

Nephrocare Health Services Limited Q2 FY27 results press release summary

NSE: NEPHROPLUS · BSE: 544647

Results press release of 3 Nov 2026, summarised by AI from the filing.

NephroPlus Q2 FY27 revenue rose 23.5% YoY to ₹303.4 cr, beating its 15-20% FY27 growth guidance, while Adj. EBITDA margin fell 443 bps to 22.7%.

Key takeaways

  1. Guidance Revenue growth guidance of 15-20% for FY27; H1 FY27 growth of 23.6% beat it.
  2. Margin Q2 FY27 Adj. EBITDA margin 22.7%, down 443 bps YoY, on clinical talent and network investment.
  3. Driver Treatments up 12.6% YoY to 21.01 lakh and revenue per treatment up 9.7% to ₹2,785 in H1 FY27.
  4. Risk Margins and returns will move during ramp-up of new markets such as Kazakhstan.

Original filing on BSE

Nephrocare Health Services Limited Q2 FY27 results

As filed: Revenue ₹303 cr, EBITDA ₹67.1 cr, PAT ₹33.5 cr, EBITDA margin 22.1%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹303 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹282 cr, EBITDA ₹63.9 cr, PAT ₹32.0 cr, EBITDA margin 22.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹282 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +4.9% in 30 days (Nifty 500: −3.1%).
  • Q4 FY26: Revenue ₹266 cr, EBITDA ₹53.8 cr, PAT ₹30.4 cr, EBITDA margin 20.2%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹266 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +11.3% in 30 days (Nifty 500: +3.0%).
  • Q3 FY26: Revenue ₹260 cr, EBITDA ₹60.9 cr, PAT ₹32.2 cr, EBITDA margin 23.4%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹260 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +4.5% in 30 days (Nifty 500: −7.8%).

Past price moves after results do not indicate future moves. Not a recommendation.

Nephrocare Health Services Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.